MARKET

SLNO

SLNO

Soleno Therapeutics Inc
NASDAQ
42.85
-0.35
-0.81%
Closed 16:01 03/27 EDT
OPEN
43.08
PREV CLOSE
43.20
HIGH
44.17
LOW
42.67
VOLUME
251.73K
TURNOVER
0
52 WEEK HIGH
53.82
52 WEEK LOW
2.100
MARKET CAP
1.39B
P/E (TTM)
-18.1261
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at SLNO last week (0318-0322)?
Weekly Report · 3d ago
Analysts Offer Insights on Healthcare Companies: Insulet (PODD), Biomea Fusion (BMEA) and Soleno Therapeutics (SLNO)
TipRanks · 6d ago
Analysts’ Top Healthcare Picks: Soleno Therapeutics (SLNO), Optinose (OPTN)
TipRanks · 03/18 11:00
Weekly Report: what happened at SLNO last week (0311-0315)?
Weekly Report · 03/18 09:51
Weekly Report: what happened at SLNO last week (0304-0308)?
Weekly Report · 03/11 09:49
Press Release: Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Soleno Therapeutics, Inc. Is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. The company announced the grant of inducement awards to five new employees under Nasdaq Listing Rule 5635(c)(4) The company is focused on the development and commercialization of novel drugs.
Dow Jones · 03/08 21:05
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Soleno Therapeutics, Inc. Is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. The grant of inducement awards to five new employees is required by Nasdaq Stock Market rules. Soleno is a company in California.
Barchart · 03/08 15:05
Viking Therapeutics, Creative Medical Technology, Aptorum Group among healthcare movers
Viking Therapeutics, Creative Medical Technology, Aptorum Group among healthcare movers in SA. S&P 500 Health Care Sector +0.22% to 1702.66. Pharmaceuticals, Biotechnology & Life Science contributes 58% to the index.
Seeking Alpha · 03/07 15:01
More
About SLNO
Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate, Diazoxide Choline Extended-Release tablets (DCCR), extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), recently completed its Phase 3 development program. DCCR is a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. DCCR’s mode of action with targets in the brain, pancreas and fat tissue has the potential to impact complex diseases like PWS to reduce appetite, reduce food seeking, improve satiety, improve insulin and leptin resistance and reduce body fat. The Company has a Fast-Track designation for DCCR in PWS and an orphan designation for the drug in the United States and the European Union.

Webull offers Soleno Therapeutics Inc stock information, including NASDAQ: SLNO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLNO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLNO stock methods without spending real money on the virtual paper trading platform.